Vancouver, British Columbia – April 10, 2013 – Sirona Biochem Corp. (TSX-V: SBM, OTCQX: SRBCF, Frankfurt: ZSB), announced today it has renewed its agreement with Ray Matthews & Associates (RM&A) to support corporate development and provide strategic advisory consulting services.
“We are pleased with the continued commitment from Ray Matthews in bringing awareness of Sirona Biochem to the investment community,” said Dr. Howard Verrico, Sirona Biochem Founder and Chairman of the Board. “Ray Matthews is well respected and will assist in the capital and institutional markets while we continue to focus on creating partnerships for our compounds and growing our organization,” said Neil Belenkie, Sirona Biochem Chief Executive Officer.
“Sirona Biochem has made significant scientific and organizational progress over the last few months, attracting the interest of international financial institutions and many of the world’s largest cosmetic and pharmaceutical companies. I’m happy to be part of the company during this exciting stage of growth,” said Ray Matthews.
About Sirona Biochem Corp.
Sirona Biochem is a biotechnology company developing diabetes therapeutics, skin depigmenting and anti-aging agents for cosmetic use, biological ingredients and cancer vaccine antigens. The company utilizes a proprietary chemistry technique to improve pharmaceutical properties of carbohydrate-based molecules. Sirona Biochem is the parent company of French-based biotechnology company, TFChem. For more information visit www.sironabiochem.com.
About Ray Matthews & Associates Inc.
Ray Matthews & Associates Inc (RM&A) is a strategic advisory firm focusing on corporate development, M&A, strategic planning and boutique IR services to Canadian and U.S.-based companies at all stages of development. For more information on RM&A Inc, please visit www.raymatthews.ca.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
For more information regarding this press release, contact:
Julie Jang
Director, Communications
Sirona Biochem Corp.
Phone: 604.282.6065
Email: jjang@sironabiochem.com
———————————————
Sirona Biochem cautions you that statements included in this press release that are not a description of historical facts may be forward-looking statements. Forward-looking statements are only predictions based upon current expectations and involve known and unknown risks and uncertainties. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of release of the relevant information, unless explicitly stated otherwise. Actual results, performance or achievement could differ materially from those expressed in, or implied by, Sirona Biochem’s forward-looking statements due to the risks and uncertainties inherent in Sirona Biochem’s business including, without limitation, statements about: the progress and timing of its clinical trials; difficulties or delays in development, testing, obtaining regulatory approval, producing and marketing its products; unexpected adverse side effects or inadequate therapeutic efficacy of its products that could delay or prevent product development or commercialization; the scope and validity of patent protection for its products; competition from other pharmaceutical or biotechnology companies; and its ability to obtain additional financing to support its operations. Sirona Biochem does not assume any obligation to update any forward-looking statements except as required by law.